Pfizer begins study of mRNA based next gen flu vax
The first participants in a Phase 1 clinical study to investigate the safety, tolerability, and immunogenicity of a single dose quadrivalent mRNA vaccine against influenza in healthy people have been dosed, according to Pfizer Inc. (NYSE: PFE). Pfizer’...
28 September, 2021
Read more